Codexis inc (CDXS) - News Archive

In a noteworthy development that emphasizes Codexis, Inc. s strategic expansion and robust performance in the competitive biopharmaceutical landscape, the company announced on November 10, 2025, the signing of a lease f...

Codexis: Cultivating Talent Through Strategic Equity Inducement in the Biotechnology SectorIn a landscape dominated by rapid advancements and intense competition, biotechnology companies are increasingly turning to inno...

Codexis Strengthens Talent Acquisition Strategy with Strategic Equity Inducement Grants Amidst Continued GrowthIn a strategic bid to enhance its talent acquisition efforts and solidify its position in the competitive bi...

Unpacking Codexis’ Latest Inducement Grants: A Strategic Move for Future GrowthOn December 6, 2024, Codexis, Inc. (NASDAQ: CDXS), a notable player in the field of enzymatic solutions aimed at optimizing therapeutics man...

Revolutionizing RNAi Therapeutics: Codexis Leads with Diverse Enzymatic Synthesis Approaches In a landmark breakthrough for RNA interference (RNAi) therapeutics, Codexis, an innovative company known for their advances i...

Codexis Inc. Strengthens Workforce with Equity Grant as Financial Recovery BeckonsIn a move that signals a renewed commitment to strategic growth and talent investment, Codexis, Inc. (NASDAQ: CDXS), a prominent player i...

In the challenging landscape of the biotechnology industry, Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions, has recently taken significant steps to enhance its financial resilience while simulta...

Unlocking Growth: Codexis Enhances Financial Resilience and Human Capital Amid Market ChallengesIn an era marked by uncertainty in the biotech sector, Codexis Inc. a prominent enzyme engineering company based in Redwood...

Codexis Announces New Employment Inducement Grants: Investing in Talent for Future GrowthCodexis, a leading enzyme engineering company based in Redwood City, California, recently announced the approval of equity grants...

Codexis, Inc. has recently finalized an asset purchase agreement with Crosswalk Therapeutics, a significant milestone in the field of gene therapy. This leading enzyme engineering company has acquired Crosswalk Therapeu...

Codexis Inc., a notable enzyme engineering company, recently announced its exclusive global licensing agreement with Roche for the Company s newly engineered double-stranded DNA (dsDNA) ligase. This breakthrough technol...

During the 12-month period ending in the third quarter of 2023, Codexis Inc reported a cumulative net loss of $-82 million. Despite this setback, the company remains optimistic and committed to pushing forward with thei...

SeqWell, a leading genomic technology company, has announced a strategic collaboration with Codexis, an innovative enzyme engineering company, to develop an engineered transposase enzyme for genomics applications. This...

Codexis Announces Strategic Partnership and Financial Results for Q3 2023Codexis Inc., a leading developer of biocatalysts, recently announced a significant development in its biotherapeutics division. The company has e...

Biotechnology company Codexis had some significant news to share recently: the successful gram-scale synthesis using its ECO Synthesis Platform. This achievement, a significant milestone for the company, enables its eng...

In a recent announcement, Codexis, Inc., a leading enzyme engineering company, revealed its participation in the 35th Annual Piper Sandler Healthcare Conference, which is scheduled to take place from November 28-30, 202...